Sector News

Lonza plots $93M expansion to capsule manufacturing, adding billions of doses per year

October 24, 2020
Life sciences

When CDMO Lonza shelled out $5.5 billion for capsule maker Capsugel in 2017, it made a big bet the booming capsule market would drive revenue. Now, with demand continuing to grow, Lonza is putting another down payment on capsules to keep up.

Lonza will spend $93 million to expand its capsule manufacturing by 15% across eight sites globally in a move to add more than 30 billion doses per year to its capacity, the Swiss manufacturer said Thursday.

The company’s expansion of its Capsugel technology manufacturing comes amid booming demand for capsules in the pharmaceutical and nutritional health fields, Lonza said. Back in 2019, Lonza bumped up capacity in its Capsules and Health Ingredients (CHI) unit, which includes the Capsugel portfolio, by 10% to keep up with demand.

Lonza’s newest investment will be doled out to eight sites including: Bornem, Belgium; Colmar, France; Greenwood, Indiana; Haryana, India; Jakarta, Indonesia; Puebla, Mexico; Sagamihara, Japan; and Suzhou, China.

The company’s capsule growth will allow Lonza to focus on next-gen dosage forms in its CHI unit, which includes lipid multiparticulates and several time-release dosages currently in the research phase, Lonza said.

When it acquired Capsugel, then a U.S.-based contract capsule and drug producer, for a cool $5.5 billion in 2017, Lonza envisioned major growth ahead as the leading manufacturer of pharmaceutical capsules.

Soon after the buyout, Lonza predicted would hit $7.9 billion in annual revenue by 2022—a number that could still be attainable. In the first half of 2020, Lonza hit $3.07 billion in revenue at about 3.3% growth.

At the time of the purchase, Capsugel touted 3,600 employees and 13 facilities on three continents.

Lonza is in a period of change after appointing a new CEO, Roche veteran Pierre-Alain Ruffieux, in June after Marc Funk ended his nine-month tenure in the top spot in November.

The company is working with Maryland biotech Moderna to produce an mRNA-based COVID-19 shot, with the partnership aiming for 1 billion doses per year if the shot secures regulatory approval.

By Kyle Blankenship

Source: fiercepharma.com

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach